Legal Representation
Attorney
Max Vern
USPTO Deadlines
Next Deadline
3612 days remaining
Section 71 Renewal Due (Principal Register 66a) (Based on registration date 20051122)
Due Date
November 22, 2035
Grace Period Ends
May 22, 2036
Application History
43 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 24, 2025 | ES71 | I | TEAS SECTION 71 RECEIVED | Loading... |
| Mar 21, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 22, 2024 | REM4 | E | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | Loading... |
| Jun 5, 2024 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Jun 5, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 5, 2024 | EWOR | I | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | Loading... |
| Jun 5, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jun 5, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 5, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jun 5, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Sep 15, 2023 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Apr 15, 2021 | RNWL | P | INTERNATIONAL REGISTRATION RENEWED | Loading... |
| Oct 26, 2017 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Sep 8, 2017 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Apr 20, 2017 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Feb 9, 2017 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Feb 9, 2017 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Jul 19, 2016 | INNA | R | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | Loading... |
| Jul 19, 2016 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... |
| Nov 19, 2015 | NA71 | E | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | Loading... |
| Nov 19, 2015 | 71AG | O | REGISTERED-SEC.71 ACCEPTED | Loading... |
| Nov 17, 2015 | ES71 | I | TEAS SECTION 71 RECEIVED | Loading... |
| Mar 27, 2014 | INNP | P | PARTIAL INVALIDATION PROCESSED BY THE IB | Loading... |
| Mar 4, 2014 | INPS | P | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | Loading... |
| Mar 27, 2013 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... |
| Jun 27, 2012 | NA71 | E | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | Loading... |
| Jun 27, 2012 | 71AG | O | REGISTERED-SEC.71 ACCEPTED | Loading... |
| Jun 27, 2012 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| May 3, 2012 | ES71 | I | TEAS SECTION 71 RECEIVED | Loading... |
| Nov 11, 2011 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Feb 25, 2011 | RNWL | P | INTERNATIONAL REGISTRATION RENEWED | Loading... |
| Jul 15, 2010 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Jun 16, 2006 | LIMG | M | LIMITATION OF GOODS RECEIVED FROM IB | Loading... |
| Feb 24, 2006 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Nov 22, 2005 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Aug 30, 2005 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 10, 2005 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| May 12, 2005 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| May 6, 2005 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 2, 2005 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 2, 2005 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 10, 2004 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
| Dec 9, 2004 | SDRC | M | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | Loading... |
Detailed Classifications
Class 001
Chemicals used in industry and science, namely, monoclonal antibodies for in vivo or in vitro scientific research and development regarding cancer [ AIDS (acquired immune deficiency syndrome), and other infectious diseases, autoimmune diseases, and cardiovascular diseases ]
Class 005
Pharmaceutical preparations based on human monoclonal antibodies for the treatment of cancer [ AIDS (acquired immune deficiency syndrome), and other infectious diseases, autoimmune diseases, and cardiovascular diseases ]
Classification
International Classes
001
005